These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 25624845)

  • 1. PON1 status evaluation in patients with chronic arterial occlusion of lower limbs due to atherosclerosis obliterans.
    Kasprzak MP; Iskra M; Majewski W; Budzyń-Napierała M; Gryszczyńska B; Strzyżewski K; Kasprzak J
    Arch Med Sci; 2014 Dec; 10(6):1101-8. PubMed ID: 25624845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arylesterase and paraoxonase activity of paraoxonase (PON1) affected by ischemia in the plasma of patients with arterial occlusion of the lower limbs.
    Kasprzak M; Iskra M; Majewski W; Wielkoszyński T
    Clin Biochem; 2009 Jan; 42(1-2):50-6. PubMed ID: 18976644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low paraoxonase 1 arylesterase activity and high von Willebrand factor levels are associated with severe coronary atherosclerosis in patients with non-diabetic stable coronary artery disease.
    Ding J; Chen Q; Zhuang X; Feng Z; Xu L; Chen F
    Med Sci Monit; 2014 Nov; 20():2421-9. PubMed ID: 25420483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paraoxonase 1 phenotype and paraoxonase activity in asthmatic patients.
    Sarioglu N; Hismiogullari AA; Erel F; Demir D; Gencer N
    Iran J Allergy Asthma Immunol; 2015 Feb; 14(1):60-6. PubMed ID: 25530140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The salt stimulation property of serum paraoxonase (PON1) could be a valuable factor in evaluating the enzyme status in ischemic stroke: the role of activity-determined PON1 192Q/R phenotypes.
    Mahrooz A; Alizadeh A; Gohari G
    J Neurol Sci; 2014 Mar; 338(1-2):197-202. PubMed ID: 24433930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paraoxonase-1 (PON1) activity as a risk factor for atherosclerosis in chronic renal failure patients.
    Saeed SA; Elsharkawy M; Elsaeed K; Fooda O
    Hemodial Int; 2008 Oct; 12(4):471-9. PubMed ID: 19090870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations of paraoxonase and platelet-activating factor acetylhydrolase activities in patients on peritoneal dialysis.
    Liberopoulos EN; Papavasiliou E; Miltiadous GA; Cariolou M; Siamopoulos KC; Tselepis AD; Elisaf MS
    Perit Dial Int; 2004; 24(6):580-9. PubMed ID: 15559488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum paraoxonase enzyme activity and oxidative stress in obese subjects.
    Aslan M; Horoz M; Sabuncu T; Celik H; Selek S
    Pol Arch Med Wewn; 2011 Jun; 121(6):181-6. PubMed ID: 21694681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levels of paraoxonase and arylesterase activities and malondialdehyde in workers exposed to ionizing radiation.
    Serhatlioglu S; Gursu MF; Gulcu F; Canatan H; Godekmerdan A
    Cell Biochem Funct; 2003 Dec; 21(4):371-5. PubMed ID: 14624476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paraoxonase/arylesterase ratio, PON1 192Q/R polymorphism and PON1 status are associated with increased risk of ischemic stroke.
    Can Demirdöğen B; Türkanoğlu A; Bek S; Sanisoğlu Y; Demirkaya S; Vural O; Arinç E; Adali O
    Clin Biochem; 2008 Jan; 41(1-2):1-9. PubMed ID: 17920578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paraoxonase Activity and Phenotype Distribution in Patients with Chronic Obstructive Pulmonary Disease.
    Sarioglu N; Bilen C; Cevik C; Gencer N
    Eurasian J Med; 2020 Jun; 52(2):161-165. PubMed ID: 32612424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paraoxonase/arylesterase in serum of patients with type II diabetes mellitus.
    Juretić D; Motejlkova A; Kunović B; Rekić B; Flegar-Mestrić Z; Vujić L; Mesić R; Lukac-Bajalo J; Simeon-Rudolf V
    Acta Pharm; 2006 Mar; 56(1):59-68. PubMed ID: 16613735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paraoxonase 1 activity in patients with chronic obstructive pulmonary disease.
    Rumora L; Rajković MG; Kopčinović LM; Pancirov D; Čepelak I; Grubišić TŽ
    COPD; 2014 Sep; 11(5):539-45. PubMed ID: 24831724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addressing the link between paraoxonase-1 gene variants and the incidence of early onset myocardial infarction.
    Rahman MF; Hashad IM; Abou-Aisha K; Abdel-Maksoud SM; Gad MZ
    Arch Med Sci; 2015 Jun; 11(3):513-20. PubMed ID: 26170843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation of Paraoxonase1, Arylesterase and Lipid Profile in Ischemic Stroke Patients.
    Chawhan SS; Mogarekar MR; Wagh RV; Das RR; Pramanik SS; Sonune SM; Chawhan SM
    J Clin Diagn Res; 2015 Nov; 9(11):BC01-3. PubMed ID: 26673997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of paraoxonase 1 (PON1) on HDL
    Miljkovic M; Stefanovic A; Vekic J; Zeljkovic A; Gojkovic T; Simic-Ogrizovic S; Bogavac-Stanojevic N; Cerne D; Ilic J; Stefanovic I; Jelic-Ivanovic Z; Spasojevic-Kalimanovska V; Kotur-Stevuljevic J
    Clin Biochem; 2018 Sep; 60():52-58. PubMed ID: 30130521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ratio of serum paraoxonase/arylesterase activity using an improved assay for arylesterase activity to discriminate PON1(R192) from PON1(Q192).
    Nakanishi M; Takanami Y; Maruyama T; Murata M; Motohashi Y; Nakano S; Uchida K; Maruyama C; Kyotani S; Tsushima M
    J Atheroscler Thromb; 2003; 10(6):337-42. PubMed ID: 15037822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased serum PON1 arylesterase activity in familial hypercholesterolemia patients with a mutated LDLR gene.
    Idrees M; Siddiq AR; Ajmal M; Akram M; Khalid RR; Hussain A; Qamar R; Bokhari H
    Genet Mol Biol; 2018 Jul/Sept.; 41(3):570-577. PubMed ID: 30044465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paraoxonase 1 Activity, Polymorphism and Atherosclerosis Risk Factors in Patients Undergoing Coronary Artery Surgery.
    Wysocka A; Cybulski M; P Wysokiński A; Berbeć H; Stążka J; Zapolski T
    J Clin Med; 2019 Mar; 8(4):. PubMed ID: 30935088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus.
    Kiss E; Seres I; Tarr T; Kocsis Z; Szegedi G; Paragh G
    Ann N Y Acad Sci; 2007 Jun; 1108():83-91. PubMed ID: 17893973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.